Several studies have shown a protective effect of diabetes mellitus (DM) on incidence of prostate cancer; however, the data are not consistent. Moreover, whether or not DM is associated with a positive result among patients referred for prostate biopsy due to abnormal PSA and/or abnormal digital rectal examination is not clear.
Introduction
Diabetes mellitus (DM) is a common disease that has known risks of significant complications, particularly in African-American (AA) patients. [1] [2] [3] In fact, the number of Americans diagnosed with DM is projected to increase by B165% over the next 50 years. 4 Because of the high prevalence of DM, a considerable amount of attention has been paid to related conditions, including various malignancies.
In general, the literature on the relation between DM and prostate cancer (PCa) seems to be inconsistent, with some studies reporting a protective effect and some showing no effect or even a positive association. [5] [6] [7] [8] [9] [10] Some of the variation in findings may relate to the duration and severity of the disease, [10] [11] [12] or the influence of hormonal alterations commonly seen in patients with DM. 13, 14 Additionally, the effect of DM on PSA levels is not fully known, though evidence suggests it may reduce levels. 15, 16 The objective of this study is to assess the association between positive biopsy and DM in a large cohort of men referred for biopsy in an equal-access health-care setting. To achieve this goal, we reviewed prospectively collected data from the biopsy database of the Atlanta VA Medical Center.
Materials and methods

Study participants and procedures
All consecutive patients who underwent transrectal ultrasound-guided prostate biopsy for elevated PSA and/or digital rectal examination (DRE) at the Atlanta VA Medical Center between January 2000 and June 2009 were considered. Patients with missing data (483 cases, 369 controls) were excluded from the analyses. Study did not involve recontacting patients, laboratory analyses of biological samples or any additional data collection. The study was approved by the Institutional Review Board.
Diabetes diagnosis
Diabetes was diagnosed according to the current criteria by the patient's primary-care provider or endocrinologist (Any of the following: symptoms of diabetes and casual plasma glucose concentration of X200 mg dl À1 , fasting plasma glucose of X126 mg dl À1 , 2 h postprandial plasma glucose of X200 mg dl À1 after 75 g glucose load or an hemoglobin A1c level 46.5%). 17 Once the diagnosis was established, it was entered in the patient's electronic medical record. Patient received standard therapy for DM to restore normal glucose control and to monitor parameters such as HgbA1c.
Study variables and data analyses
The primary endpoint of interest was the result of prostate biopsy, which was expressed as a binary Yes We performed analyses using SAS v9.2 for Windows (SAS Institute, Cary, NC, USA). Frequencies and percentages were computed to summarize demographic characteristics and covariates in cases (that is, patients whose biopsies were positive for PCa) and controls (that is, patients whose biopsy showed no evidence of malignancy). The distribution of demographic and other patient-related characteristics in cases and controls were compared using w 2 tests accompanied by P-values. In addition, the association of PSA and DM was examined. Unconditional logistic regression was used to ascertain the association between PCa and DM while controlling for potential confounding factors. 18 A significant interaction between PSA and prostate examination was reported in a previous study, 19, 20 and for this reason, an interaction term was included in the regression models. All models were also tested for interaction between DM and each covariate. The results of the logistic regression analyses were expressed as odds ratios (ORs) with corresponding 95% confidence intervals (CI). Separate multivariable analyses were also performed to compare cases with high (X7) Gleason scores to biopsy-negative controls, as well as to compare the PCa-DM association in elevated PSA and abnormal DRE subgroups.
Results
The demographic and clinical data are summarized in Table 1 . A total of 2310 patients were included for analysis. Patients with positive biopsy included greater proportions of AA men and those 65 years of age or older. Additionally, smaller prostate volume, higher PSA and abnormal DRE were associated with positive biopsy. However, PSA levels did not differ in patients with and without DM. The proportions of persons with PSAo4, 4-10 and over 10 ng ml À1 were 19, 56 and 25%, respectively among patients with DM, and 16, 58 and 26%, respectively among those without DM (P ¼ 0.30). A higher proportion of patients with negative biopsy were overweight (46.5 versus 41.1%). AA patients with positive biopsy were younger and had more aggressive disease (Gleason X7) (data not shown, but previously published 21 ).
There was no evidence of interaction between race and any of the other independent variables (including DM); however, as reported previously, we found significant interaction between PSA and prostate exam in all models (Po0.001). 19, 20 The crude, adjusted and stratified ORs reflecting the association between DM and positive biopsy are summarized in Table 2 . Subjects with DM had significantly increased odds of positive biopsy compared with those without DM (adjusted OR 1.26, 95% CI: 1.01-1.55; P ¼ 0.04). These results did not differ by race, although racespecific results were no longer statistically significant due to reduced sample size in each stratum. Additionally, the association between diabetes and biopsy results was examined by reason for referral. Among persons with low PSA (o4 ng ml À1 ) the adjusted OR was 1.02 (95% CI: 0.57, 1.81), for persons with PSA 4-10 ng ml À1 adjusted OR was 1.37 (95% CI: 1.04, 1.79), and for persons whose PSA was over 10 ng ml À1 adjusted OR was 1.22 (95% CI: 0.79-1.87). The corresponding adjusted OR for persons with positive DRE (regardless of PSA) was 1.17 (95% CI: 0.84-1.63).
Discussion
The study demonstrates that men with DM have increased odds of positive prostate biopsy, compared with those without DM. Additionally, men with DM are more likely to be diagnosed with more aggressive disease at the time of biopsy. This study focuses particularly on a group of patients referred for prostate biopsy, either for elevated PSA or abnormal DRE. It differs in approach from previous studies that have quantified the overall incidence of PCa in persons with and without DM. The series included a significant percentage of AAs, allowing for meaningful comparison of the results among AAs to those among whites in an equal-access health-care setting.
The association of DM and PCa has been studied by several groups with mixed results, though the majority of studies show an inverse association. In a recent study of over 4 million US veterans with DM, Atchison et al. 22 found a 7% reduction in overall cancer risk, and a statistically significant 11% decrease in risk of PCa when compared with those without DM.
Similarly in a pre-PSA era Swedish study of cancer risk in over 23 000 men with DM, there was a 30% reduction in PCa incidence. 6 In contrast, other groups in North America and Europe have shown no relation of PCa to DM. 5, 8 Current literature indicates that the association between DM and PCa risk may vary depending on disease duration and severity. In the previously discussed Swedish study, there was an almost threefold increased risk of PCa in men with o1 year follow-up after diagnosis of DM and a slightly increased PCa-specific mortality within the first 4 years of DM diagnosis. 6 In another study of 1616 men in Italy and Greece, Tavani et al. 8 found a nonsignificant increased risk (OR 2.04) of PCa diagnosis in men with DM diagnosed within the previous 5 years, whereas men diagnosed with DM within 5-9 years or X10 years had no increase in risk. Similar analyses of other cohort studies generally confirmed that recently diagnosed DM increases the risk of PCa. 11, 12 Another important line of evidence comes from studies of men with complications from DM (that is, those with long-standing disease), which tend to show an inverse association with PCa. For example, among 2455 men from a European study, the greatest risk reduction of PCa was among men with DM who were hospitalized owing to complications. 23 Alterations of hormones such as testosterone, SHBG, leptin, insulin and insulin-like growth factor (IGF) levels in patients with DM may influence the risk of PCa. 13, 14, 24 IGF-1 has been a subject of study owing to its role in proliferation of PCa cells in vitro, as well as associations seen with increased risk in population-based studies. Stattin et al. 25 compared IGF-1 levels in blood samples drawn from men before their PCa diagnosis to a matched cohort of men without PCa. They found that increased levels of IGF-1 were significantly associated with PCa, particularly in men younger than 60 years of age. The relationship of DM and circulating plasma IGF-1 levels may have a significant role in the overall risk of PCA in men with DM. 26 In a small multicenter study from Baradaran et al., 13 the hormonal profiles of men with DM with and without PCa were compared. They found that men with PCa had significantly lower testosterone, estradiol and testosterone/SHBG ratio. Additionally, Table 2 Overall and subanalyses of the association between DM and prostate cancer among patients referred for biopsy
Risk factor
Crude OR (95% CI) Adjusted OR (95% CI) P-value . 27 In another study from the SEARCH group, the authors found an association of higher BMI and odds of PCa diagnosis, although men with higher BMI were found to have lower PSA. 28 An analysis of the Physicians' Health Study found that higher BMI and plasma C-peptide concentration (a marker for insulin secretion) were associated with elevated risk of PCa diagnosis and mortality. 29 The disparate findings in hormonal profile in those with DM and the potential role in PCa risk serve as a basis for further basic and clinical studies elucidating the pathways that link these common diseases.
We found that DM is potentially associated with more aggressive disease (Gleason X7). This finding is similar to Jayachandran et al., 30 who found that men with DM undergoing radical prostatectomy had greater odds of higher tumor grade and seminal vesicle invasion. These findings did not translate to increased risk of biochemical recurrence or faster PSA doubling time at the time of recurrence. In a study from Korea, Hong et al. 31 found that men with DM presenting for prostate biopsy were more likely to have high-grade disease in their positive biopsy cohort (Gleason 46). Montorsi and colleagues, 32 in a study of 2060 men who underwent prostatectomy, compared patients with and without DM to determine the rate of high-grade disease (Gleason X8). They found that a higher percentage of men with DM had high-grade disease on biopsy and in the prostatectomy specimen. Men with DM had a 42-times risk of highgrade disease on multivariable analysis. Investigators at Duke University found that among men with DM, obese white men had a higher risk of aggressive disease, but not obese AA men. 33 This is quite interesting in light of data showing that obese AA men demonstrate more aggressive pathologic features compared with non-AA men in a radical prostatectomy cohort. 34 Whether or not DM attenuates this effect remains to be seen.
In the ProtecT study from the United Kingdom, Turner et al. 16 found in men with DM that an inverse association was greater for well-differentiated versus poorly differentiated cancers, though there was no association with regard to duration of DM. In contrast, Giovannucci et al. 11 reported a 33% reduction in aggressive disease (Gleason X7 and extraprostatic extension). There are no known studies defining the relationship of prostate histology and DM on a molecular level; however, the hormonal milieu likely has a role.
Limitations of this study include the inability to account for the length and severity of DM in the patient population, as well as the retrospective nature of the study. Additionally, the conclusions regarding the influence of race and positive biopsy would likely be strengthened with increased numbers. We did find that AA men were more likely to be younger and have more aggressive disease (data not shown), a finding that we showed in a previous study that showed that the association between biopsy results and low-density lipoprotein cholesterol levels is modified by race. 21 However, in the current analysis, there was no evidence that the association between DM and PCa was different in AAs and whites.
Conclusion
This study identifies a positive association of DM to PCa in a population referred for prostate biopsy in a large US veteran population. Further, there was an association of DM and more aggressive disease evidenced by higher pathological Gleason grade. Race did not have an impact on this relationship. As the existing literature on DM and PCa remains inconsistent, more studies are needed to further define the relationship and interactions between these two conditions.
